Astrocytic expression of GFAP and serum levels of IL-1β and TNF-α in rats treated with different pain relievers by Amaral, Gisele Ferreira et al.
*Correspondence: E. Bondan. Departamento de Patologia Ambiental e Ex-
perimental. Universidade Paulista, Rua Caconde, 125/51 - 01425-011 - São 




leBrazilian Journal of 
Pharmaceutical Sciences
vol. 52, n. 4, oct./dec., 2016
http://dx.doi.org/10.1590/S1984-82502016000400006
Astrocytic expression of GFAP and serum levels of IL-1β and TNF-α 
in rats treated with different pain relievers
Gisele Ferreira Amaral1, Pietro Domingues Dossa1, Lígia Bocamino Viebig1, Fabiana Toshie 
Camargo Konno1, Amanda Consoli2, Maria de Fátima Monteiro Martins1,3, Flávio Cesar Viani3, 
Eduardo Fernandes Bondan1,3*
1Department of Environmental and Experimental Pathology, University Paulista, São Paulo, SP, Brazil, 2Department of 
Psychobiology, Federal University of São Paulo, São Paulo, SP, Brazil, 3Department of Veterinary Medicine, University 
Cruzeiro do Sul, São Paulo, SP, Brazil
Pro-inflammatory cytokines and glial cells, especially microglial cells, have been implicated in 
persistent pain sensitization. Less is known about the role of astrocytes in pain regulation. This study 
aimed to observe the expression of the astrocytic biomarker glial fibrillary acidic protein (GFAP) and 
the serum levels of interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) after short-term 
administration of central pain relievers in rats not submitted to noxious stimuli. Male Wistar rats were 
divided into five groups, receiving for nine days- (1) amitriptyline (Amt-10 mg/kg/day, by gavage); (2) 
gabapentin (Gb-60 mg/kg/day, by gavage; (3) methadone (Me-4.5 mg/kg/day, intraperitoneal route [IP]); 
(4) morphine (Mo-10 mg/kg/day, IP); or (5) 0.9% saline solution, IP. Brain samples were collected for 
immunohistochemical study of GFAP expression in the mesencephalon and nucleus accumbens (NAc). 
The area of GFAP-positive cells was calculated using MetaMorph software and serum levels of IL-1β 
and TNF-α were measured by enzyme-linked immunosorbent assay. Serum TNF-α levels were decreased 
in the groups treated with Mo, Me and Gb, but not in the Amt-treated group. IL-1β decreased only in 
rats treated with Me. The astrocytic expression of GFAP was decreased in the brainstem with all drugs, 
while it was increased in the NAc with Amt, Me and Mo.
Uniterms: Neuropathic pain/treatment. Astrocytes/pain regulation. Analgesics/tests/treatment. Cytokines. 
Glial Fibrillary Acidic Protein/study
INTRODUCTION
Although pain is traditionally considered to be 
neuronally mediated, recent research shows an important 
role of glial cells in persistent pain sensitization. There is 
abundant evidence that certain pro-inflammatory cytokines 
such as interleukin 1 beta (IL-1β) and tumor necrosis factor 
alpha (TNF-α) are involved in the process of pathological 
pain (Watkins, Milligan, Maier, 2003; Hutchinson et al., 
2007; Ji, Berta, Nedergaard, 2013) and many pain relievers 
are known to diminish central and peripheral cytokine 
production (De Waal, Van Der Laan, Van Loveren, 1998; 
Kenis, Maes, 2002; Hutchinson, Somogyi, 2004; Vallejo, 
De Leon-Casasola, Ramsun, 2004; Sacerdote, 2006; Bao 
et al., 2014). Moreover, blood-borne cytokines have been 
shown to cross the blood-brain barrier, despite their large 
size and low lipid solubility, by using bidirectional and 
saturable transport systems (Banks, Kastin, Broadwell, 
1995), thus permitting the existence of cross-talk between 
the immune and neuroendocrine systems in the so-called 
neuroimmune-endocrine axis.
Pain modulation exists in the form of a descending 
modulatory circuit with inputs that arise in multiple 
sites, including the hypothalamus, the amygdala and 
the rostral anterior cingulate cortex, feeding to the 
midbrain periaqueductal gray matter (PAG) and with 
outputs from the PAG to the medulla oblongata. Neurons 
within the nucleus raphe magnus and nucleus reticularis 
gigantocellularis, which are included within the rostral 
ventromedial medulla, have been shown to project to the 
spinal dorsal horns to, directly or indirectly, enhance or 
diminish nociceptive traffic, thus changing the experience 
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of pain (Ossipov, Dussor, Porreca, 2010). These “top-
down” modulatory pathways are opioid-sensitive and the 
actions of, for example, exogenous or endogenous opiates, 
cannabinoids, serotonin/norepinephrine reuptake blockers, 
and nonsteroidal anti-inflammatory drugs, mimic, in part, 
the actions of opiates.
Although microglial cells have been widely 
implicated in the development of chronic pain, less is 
known about the role of astrocytes in its regulation. Due to 
the complexity of the central circuitry for pain modulation, 
the precise mechanisms by which distinct pain relievers 
act remain unknown, as well as the effects of such drugs 
on central nervous system (CNS) cells - neurons and glial 
cells, especially astrocytes. 
Pain modulators include a wide variety of drugs, 
with distinct mechanisms of action, such as tricyclic 
antidepressants (TCAs) that act primarily as serotonin/
norepinephrine reuptake inhibitors (e.g., amitriptyline 
- Amt), opioid agonists (e.g., morphine – Mo - and 
methadone - Me) and GABAergic medications that 
modulate the activity of chloride channels (e.g., gabapentin 
- Gb) (Lynch, Watson, 2006).
Many different types of signalling molecules are 
able to trigger and/or regulate astrocyte function and can 
be released by all cell types of the CNS tissue, including 
neurons, microglia, oligodendrocyte lineage cells, 
pericytes, endothelia and other astrocytes, as well as by 
invasive inflammatory/immune cells. These molecular 
signals include (a) large polypeptide growth factors and 
cytokines; (b) mediators of innate immunity such as 
lipopolysaccharide and other Toll-like receptor ligands; 
(c) neurotransmitters such as glutamate, dopamine and 
norepinephrine; (d) purines (e.g., adenosine triphosphate); 
(e) reactive oxygen species; (f) products associated 
with systemic metabolic activity (e.g., ammonium) and 
(g) regulators of cell proliferation, such as endothelin 
(Sofroniew, 2009). Astrogliosis may be induced by 
molecular signals that stimulate astrocyte activity and/or 
affect neurotransmitter release (Sofroniew, Vinters, 2010).
In such context, the aim of this study was to determine, 
after the administration of short-term therapeutic doses of 
Amt, Gb, Me or Mo in rats not submitted to any noxious 
stimuli, the astrocyte response in the mesencephalon and 
nucleus accumbens (NAc), through the expression of the 
astrocytic biomarker GFAP (glial fibrillary acidic protein), 
as well as the possible changes in the serum levels of IL-1β 
and TNF-α by such drugs.
MATERIAL AND METHODS
The animal procedures were performed in accordance 
with the guidelines of the Committee on Care and Use of 
Laboratory Animal Resources and Brazilian Institutional 
Ethics Committee guidelines, Universidade Paulista 
(protocol no. 235/14, CEUA/ICS/UNIP, 16/04/2014). 
The experiments were performed in accordance with good 
laboratory practice protocols and all efforts were made to 
minimize the suffering of the animals.
Male Wistar rats were divided into five groups 
of six individuals, receiving for nine days - (1) 0.9% 
saline solution by the intraperitoneal route (IP); (2) Mo 
(10 mg/kg/day, IP); (3) Me (4.5 mg/kg/day, IP); (4) Gb 
(60 mg/kg/day, by gavage); or (5) Amt (10 mg/kg/day, 
by gavage). On the tenth day, the rats were anaesthetized 
with xylazine combined with ketamine (10 mg/kg and 
90 mg/kg, respectively, IP) and tiopenthal (30 mg/kg, 
IP) for thoracotomy, and blood was collected by cardiac 
puncture. The samples were centrifuged in 5 mL conical 
tubes at 1500g for 15 minutes and serum was stored at -80° 
C. The rats were immediately subjected to intracardiac 
perfusion with buffered 10% formaldehyde solution. 
Their brains were then removed and kept for at least 48 
hours in the same fixative for immunohistochemical study 
of GFAP expression in the mesencephalon and NAc. 
Coronal sections were made to collect the NAc and the 
mesencephalon and the tissue was embedded in paraffin 
for processing according to conventional histological 
procedures. The NAc area was chosen due to its role in 
processing rewarding and/or reinforcing stimuli, and the 
mesencephalon (PAG), for its participation in the pain 
desensitization pathway. The expression of the astrocyte 
marker GFAP was analyzed using immunohistochemical 
staining in sections of the mesencephalon and NAc from all 
groups. Coronal sections were mounted on silanized slides 
and submitted to GFAP immunostaining using the avidin-
biotin peroxidase complex method, according to Bondan 
et al. (2013). Briefly, the sections were deparaffinized 
in xylene and rehydrated in a crescent-graded series of 
ethanol solutions. Antigen retrieval was achieved by 
transferring the slides to 10 mM sodium citrate buffer 
(pH 6.0) at 95° C for 20 minutes. Endogenous peroxidase 
was blocked by 3% hydrogen peroxide for 10 minutes at 
room temperature. Two washes with Tris/HCl buffer pH 
6.0 (Wash buffer 10x, S3006, Dako, Glostrup, Danmark) 
were performed between incubations. Polyclonal rabbit 
anti-GFAP immunoglobulin (Z0334, Dako), at a dilution 
of 1:1000, was used as the primary antibody, for 16 hours, 
followed by the application of a biotinylated secondary 
antibody (Dako Universal LSABTM 2 System - HRP, 
K0690), according to the manufacturer`s instructions. 
Immunoreactivity was visualized by incubating the 
sections in a solution containing 0.1% diaminobenzidine 
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(DAB, K3467, Dako). Sections were then counterstained 
by Harris´ modified haematoxylin solution, dehydrated 
and mounted in Entellan (Merck, Germany). Negative 
controls for immunostaining (sections lacking primary 
antibody application) were also prepared.
Ten photomicrographs of each mesencephalon 
section and four of each NAc section were randomly 
taken with the same microscope using a 40x objective. 
The area of astrocyte processes, marked in brown, was 
automatically calculated in pixels using MetaMorph® 
software that was calibrated with digital colour filters that 
regulated red, green, and blue areas, in such a manner that 
only positive cells were included and background staining 
was excluded from the measurement. 
Serum levels of IL-1βb and TNF–α were determined 
in triplicate using an enzyme-linked immunosorbent 
assay (ready-to-use sandwich ELISA) according to the 
manufacturer’s instructions (rat IL-1β Platinum ELISA kit, 
BMS630, and rat TNF-α Platinum ELISA kit, BMS622, 
eBioscience, San Diego, California, USA).
For statistical analyses, homoscedasticity was 
veriﬁed using Bartlett’s test. Normality was veriﬁed using 
the Kolmogorov-Smirnov test. Data were analyzed by one-
way analysis of variance (ANOVA) and Tukey-Kramer 
multiple comparisons test. Statistical significance was set 
at p < 0.05.
RESULTS
No mortality was found in rats treated with the doses 
and drugs used in this experiment. 
The serum levels (in pg/dL) of TNF-α and IL-1β 
from the experimental groups are presented, respectively, 
in Figures 1 and 2. It was observed that, on the tenth day 
of the experiment, TNF-α decreased compared to control 
rats (968.31±88.66 pg/dL) in the groups receiving Gb 
(484.53±70.28 pg/dL), Mo (388.53±17.37 pg/dL) and 
Me (451.87±22.47 pg/dL), but not in the Amt-group 
(867.87±61.57 pg/dL). Highly significant differences (p 
< 0.001) were seen between groups Amt vs. Gb, Amt vs. 
Mo and Amt vs. Me. A significant difference (p < 0.05) 
was found between Gb vs. Mo groups.
As for IL-1β, serum levels decreased only in the 
group treated with Me (261.56±41.79 pg/dL) compared to 
control rats (404.52±95 pg/dL, p < 0.05) and no significant 
differences were seen between groups that received the 
drugs for pain relief.
The expression of the astrocytic marker GFAP 
(represented in total pixel counts) in the mesencephalon 
and in the NAc can be seen, respectively, in Figures 3 
and 4. In the mesencephalon, GFAP immunoreactivity 
decreased (p < 0.001) in the groups treated with Amt 
(24,031.48±20,235.34 pixels), Gb (31,033.12±15,923.32 
pixels), Me (14,713.75±13,744.54 pixels) and Mo 
(11,004.82±6,593.14 pixels) in relation to controls 
(42,243±14,916.46 pixels). Significant differences were 
found between Mo vs. Amt (p < 0.001) , Mo vs. Gb (p < 
0.001), Me vs. Amt (p < 0.01), Me vs. Gb (p < 0.001) and 
Gb vs. Amt (p < 0.05), but not in Mo vs. Me. As for the NAc, 
GFAP increased (p < 0.001) in the groups treated with Amt 
(20,382.75±14,830.65 pixels), Me (24,075.04±21,023.05 
pixels) and Mo (37,232.63±21,888.26 pixels), compared 
FIGURE 1 - Serum concentrations (represented as mean ± standard deviation) of TNF-α (pg/dL) in the different experimental groups 
(n=6 per group). AMT - amitriptyline; GB - gabapentin; ME - methadone; MO - morphine; CONT - control group. Data were 
analyzed by one-way ANOVA followed by Tukey-Kramer test. Asterisks show significant differences for comparisons between 
drug group vs. control group. Bars show differences between drug groups. *p < 0.05; ***p < 0.001.
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to controls (5,602.0±4,797.88 pixels), but not in the Gb-
group (3,827.58±3,579.64 pixels). Significant differences 
were found between Mo vs. Amt (p < 0.01), Mo vs. Gb (p 
< 0.001), Mo vs. Me (p < 0.05), Me vs. Gb (p < 0.001), 
Me vs. Gb (p < 0.001) and Gb vs. Amt (p < 0.001), but 
not in Me vs. Amt.
Astrocytic GFAP immunoreactivity in the 
mesencephalon and NAc of the different experimental 
groups are, respectively, presented in Figures 5 and 6.
DISCUSSION
Activation of glial cells and neuro-glial interactions 
are emerging as key mechanisms underlying chronic pain 
(Watkins, Milligan, Maier, 2003). Accumulating evidence 
has implicated three types of glial cells in the development 
and maintenance of chronic pain, namely the microglia and 
astrocytes of the CNS and the satellite glial cells of the dorsal 
root and trigeminal ganglia (Ji, Berta, Nedergaard, 2013).
FIGURE 2 - Serum concentrations (represented as mean ± standard deviation) of IL-1β (pg/dL) in the different experimental groups 
(n=6 per group). AMT - amitriptyline; GB - gabapentin; ME - methadone; MO - morphine; CONT - control group. Data were 
analyzed by one-way ANOVA followed by Tukey-Kramer test. Asterisk shows significant difference for comparison between drug 
group vs. control group. *p < 0.05. No differences were found between AMT, GB, ME and MO groups.
FIGURE 3 - Total count in pixels of GFAP immunoreactive astrocytes (represented as mean ± standard deviation) in the 
mesencephalon from the different experimental groups (n=6 per group). AMT - amitriptyline; GB - gabapentin; ME - methadone; 
MO - morphine; CONT - control group. Data were analyzed by one-way ANOVA followed by Tukey-Kramer test. Asterisks show 
significant differences for comparisons between drug group vs. control group. Bars show differences between drug groups. *p < 
0.05; **p < 0.01; ***p < 0.001.
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A number of events, including CNS injury, infection 
and pain states, lead to hypertrophy of both microglia and 
astroglia, with a concomitant increased production of a 
variety of proinflammatory cytokines and other potentially 
pain-enhancing substances. Increased numbers of such cells 
and expression of markers such as OX-42 (for microglia) 
and GFAP (for astrocytes) can be used to identify glial 
cell activation (McMahon, Cafferty, Marchand, 2005). 
Microglia appear to be more important in the initial phases 
of neuropathic pain, while astrocytes are more relevant 
for later phases (Raghavendra, Tanga, DeLeo, 2004). 
Although glial activation has been extensively studied in 
the spinal cord (Scholz, Woolf, 2007), less is known about 
the microglial and astrocyte responses in brain areas when 
a noxious stimulus is applied to the periphery.
Current therapeutic strategies for neuropathic pain 
aim to reduce the excitability of neurons in the peripheral 
nervous system (PNS) or the CNS by modulating the 
activity of ion channels (Gb, pregabalin, carbamazepine, 
lidocaine and capsaicin) or by mimicking and enhancing 
endogenous inhibitory mechanisms (TCAs, duloxetine 
and opioids). Preclinical studies have explored other 
routes for neuropathic pain relief by modulating immune 
and glial responses. For example, global inhibitors of 
glial metabolism, such as fluorocitrate, propentofylline, 
minocycline and teriflunomide, reduce cytokine release 
and attenuate pain-responsive behaviour in several animal 
models of neuropathic pain (Scholz, Woolf, 2007).
When astrocytes and microglia are not in their 
activated state, they do not appear to be important regulators 
of pain transmission; however, when glia become activated, 
pain is affected. Peripheral immune-activated signalling to 
the CNS induces sickness responses, including enhanced 
pain responsivity, fever, increase in sleep, decreases in food 
and water intake, and generalized suppression of behaviour 
(Watkins et al., 2007).
Opioids such as Mo and Me are known to have 
profound suppressive effects on the immune system 
(Van der Laan et al., 1995; De Waal, Van der Laan, Van 
Lovenren, 1998; Hutchinson, Somogyi, 2004). Three 
distinct opioid receptor classes have been identified and 
cloned, and are designated μ-, κ- and δ, and all of them are 
widely distributed in the CNS and PNS. The expression 
of opioid receptors on cells of the immune system was 
first implicated by the ability of opioids to alter immune 
functions (Rittner, Machelska, Stein, 2005). Different 
opioids have been reported to exert immunosuppressive 
and modulatory effects on a variety of immune cells, 
including T and B cells, macrophages and natural killer 
(NK) cells. Moreover, they have been shown to diminish 
the levels of inflammatory cytokines, including IL-2, 
interferon gamma (IFN-γ), and TNF-α, while enhancing 
the levels of anti-inflammatory cytokines like IL-4 during 
immune/inflammatory processes (Suo, Weber, 1998; 
Sacerdote, 2006; Kafami et al., 2013). Methadone (Me), 
for instance, a potent μ-opioid receptor agonist, has been 
shown to diminish neuroinflammation and severity of 
symptoms in experimental autoimmune encephalomyelitis 
(Kafami et al., 2013). On the other hand, Monibi et al. 
(2015) did not find any alteration in leucocyte TNF-α, IL-
FIGURE 4 - Total count in pixels of GFAP immunoreactive astrocytes (represented as mean ± standard deviation) in the NAc 
from the different experimental groups (n=6 per group). AMT - amitriptyline; GB - gabapentin; ME - methadone; MO - morphine; 
CONT - control group. Data were analyzed by one-way ANOVA followed by Tukey-Kramer test. Asterisks show significant 
differences for comparisons between drug group vs. control group. Bars show differences between drug groups. *p < 0.05; **p < 
0.01; ***p < 0.001.
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6, IL-10 production, on early leucocyte apoptosis and on 
neutrophil phagocytic function after a 24-hour infusion of 
morphine (Mo) or buprenorphine in healthy dogs.
Our results show that healthy rats treated for nine 
days with the opiate agonists Mo and Me presented 
decreased serum levels of TNF-α, although only Me 
decreased IL-1β. Gb-treated rats also exhibited decreased 
serum levels of TNF-α. The rats used in this investigation 
were apparently healthy and were not submitted to any 
noxious stimuli, inflammation or damage to the PNS/
CNS or at peripheral sites; despite this, acute opioid 
administration is known to have inhibitory effects on 
humoral and cellular peripheral immune responses 
including antibody production, NK cell activity, cytokine 
expression, and phagocytic activity. Opiates behave like 
cytokines, modulating the immune response by interacting 
with their receptors in the CNS and in the periphery 
(Vallejo, De Leon-Casarola, Ramsun, 2004).
FIGURE 5 - Astrocytic immunostaining for GFAP in the ventral surface of the mesencephalon of the different experimental groups. 
Amt - amitriptyline; Gb - gabapentin; Me - methadone; Mo - morphine; Cont - control group. Bar = 50 μm.
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The PAG of the mesencephalon has been reported 
to be one of the primary neural foci for the action of 
centrally administered Mo in eliciting the suppression 
of splenic NK cell activity. This immunosuppression 
has been hypothesized to be due to the activation 
of the hypothalamic-pituitary-adrenal axis or of the 
sympathetic nervous system or both. Although PAG 
is involved in the regulation of many physiological 
functions including pain, fear and anxiety, autonomic 
regulation, vocalization, aggressive and reproductive 
behavior, the relationship between PAG and immunity 
remains obscure (Suo, Weber, 1998; Vallejo, De Leon-
Casarola, Ramsun, 2004).
GABAergic medications, such as Gb, appear to 
reduce the reinforcing effects of cocaine by attenuating 
cocaine-induced dopamine release in the NAc and corpus 
striatum (Gerasimov et al., 2001; González et al., 2007). 
Gabapentin (Gb) also enhances the antinociceptive effect 
FIGURE 6 - Astrocytic immunostaining for GFAP in the core region of the NAc of the different experimental groups. Amt - 
amitriptyline; Gb - gabapentin; Me - methadone; Mo - morphine; Cont - control group. Bar = 50 μm.
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of Mo and attenuates Mo tolerance probably through up-
regulation of the anti-inflammatory cytokine IL-10 and 
inhibition of proinflammatory cytokines in the rat spinal 
cord (Lee et al., 2013; Bao et al., 2014); effects that may 
explain the decreased TNF-α levels in the Gb-treated 
rats from our investigation. Rossi and colleagues (2013) 
demonstrated that Gb also reduced reactive gliosis and 
dendritic loss caused by glutamate excitotoxicity after 
pilocarpine-induced status epilecticus.
Administration of Amt in association with Mo not 
only has preserved the antinociceptive effect of Mo, but 
also attenuated astrocyte activation in the rat spinal cord 
dorsal horn (Huang et al., 2012). It also up-regulated 
glutamate transporters in Mo-tolerant rats, attenuating 
Mo tolerance, and suppressed neuroinflammation in this 
site by inhibiting pro-inflammatory cytokine (TNF-α, 
IL-1β, IL-6) expression (Tai et al., 2006). In vitro 
studies with human whole blood have also reported 
that TCAs (e.g. imipramine and clomipramine) and 
selective serotonin reuptake inhibitors (e.g. citalopram 
and sertraline) were able to inhibit the production of the 
proinflammatory cytokines IL-1, IL-2, IL-6, TNF-α, 
IFN-γ, while stimulating the negative immunoregulatory 
cytokine IL-10 (Kenis, Maes, 2002; Schiepers, Wichers, 
Maes, 2005). Our results showed that Amt did not affect 
TNF-α and IL-1β levels in serum. Although there are many 
conflicting results in the literature, the lack of effects of 
antidepressants on cytokine release in humans was also 
found by Anisman et al. (1999) and Rothermundt et al. 
(2001), in relation to IL-1β production, and by Landmann 
et al. (1997) for TNF-α.
Glial fibrillary acidic protein (GFAP) is the main 
intermediate filament protein in mature astrocytes, 
and up-regulation of its expression is one of the main 
characteristics of the astrocyte reaction commonly 
observed after CNS injury (Middeldorp, Hol, 2011). 
The exact function of GFAP remains obscure, despite 
the huge number of studies using it as a marker for 
astrocytes; however, it has been suggested that GFAP 
helps astrocytes to maintain mechanical strength, as 
well their shape (Middeldorp, Hol, 2011). TNF-α, a 
pluripotent cytokine that is reportedly mitogenic to 
astrocytes, is associated with the overexpression of 
GFAP, probably via activation of the mitogen activated 
protein kinase (MAPK) termed Erk2 (extracellular 
signal-regulated protein kinase) (Zhang et al., 2000). 
Interleukin 1 beta (IL-1β) is also identified as a potent 
inducer of several members of the TNF superfamily, 
as well as chemokines, growth factors, extracellular 
matrix proteins and matrix metalloproteinases, although 
repressing genes of the transforming growth factor (TGF) 
family and cytoskeleton proteins (John et al., 2005). 
Human fetal astrocyte cultures showed, after hours of 
stimulation with IL-1β, a morphological conversion 
from flat, polygonal cells to small, contracted, highly 
branched cells, displaying intense GFAP and vimentin 
immunoreactivity in the perikarya and processes.
The periaqueductal gray (PAG) matter of the 
midbrain plays a key role in the central analgesic system 
(for review, see Ossipov, Dussor, Porreca, 2010). In our 
study, GFAP immunoreactivity in the mesencephalon 
tended to diminish in rats treated with Amt, Gb, Me and 
Mo compared to the control group. Lazriev et al. (2001) 
showed that high doses of Mo appeared to decrease 
the total length of astrocyte processes and branching of 
individual astrocytes in the caudate nucleus. However, it 
induced hyperplasia and elongation of astrocytic processes 
in the NAc and lateral septal nucleus.
In contrast, Song and Zhao (2001) demonstrated 
that chronic Mo administration caused glial activation in 
the spinal cord and brain, and co-administration of Mo 
with a glial activation inhibitor resulted in maintenance of 
analgesic efficacy and a corresponding reduction of glial 
activation. They linked for the first time opioid-induced 
glial activation with the development of tolerance. A 
dose of 50 mg/kg/day (a dose five times greater than the 
dose used in our investigation) by the IP route was used 
for nine days to induce systemic tolerance and on the 
tenth day its analgesic effect disappeared as detected by 
behavioral testing. In these systemically Mo-tolerant rats, 
GFAP immunostaining was increased significantly in the 
spinal cord, posterior cingulate cortex and hippocampus, 
but not in the thalamus and this increase was attributed 
primarily to hypertrophy of astrocytes rather than their 
proliferation or migration since counts of astroglial cells 
demonstrated no significant difference compared with the 
control group. It is important to notice that, in contrast 
with the investigation performed by Song and Zhao (2001) 
with Mo, our investigation has used (for all drugs) doses 
that are equivalent to the therapeutic ones and no noxious 
stimulus was applied to produce pain.
The  mos t  cha rac t e r i zed  change  in  b ra in 
neurochemistry caused by drugs of abuse is an increase 
in extracellular dopamine levels in the NAc of the basal 
forebrain, and the findings of many studies suggest that 
this plays a pivotal role in the rewarding and positive 
reinforcing effects of μ-agonists, like Mo (Olds, 1982; 
Pontieri, Tanda, Di Chiara, 1995) and Me (Di Chiara, 
Imperato, 1988). Di Matteo et al. (2000) showed that 
administration of Amt also increased dopamine release 
in the rat NAc, suggesting the possible involvement of 
serotonin 5HT2C receptors. Peng et al. (2008), in turn, 
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failed to demonstrate any alteration of the dopamine 
level within the NAc using Gb or even after cocaine self-
administration, cocaine-triggered relapse and cocaine-
enhanced NAc dopamine in rats. Our results suggest 
that drugs which, according to previous studies, exhibit 
the capacity of increasing dopamine concentrations 
in the NAc, such as Amt, Me and Mo, also induced an 
increased GFAP immunoreactivity in this region, probably 
by enhancing the astrocyte activity of clearing excess 
dopamine. It is recognized that this neurotransmitter 
may be actively and specifically removed from the 
extracellular space by astrocytes and neurons through (1) 
dopamine transporters and, afterwards, either recycled 
into vesicles or (2) metabolized by the glial/neuronal 
enzymes monoamino oxidase B (MAO B) and catechol-
O-methyl transferase (COMT) (Karakaya, Kipp, Beyer, 
2007). Excess dopamine can cause auto-oxidation to 
ortho-quinone and consequently oxidative damage and 
schizophrenia-like symptoms (Whitehead et al., 2001).
CONCLUSION
Serum TNF-α levels decreased in the groups that 
received short-term doses of Mo, Me and Gb, but not 
in the Amt-treated group. On the other hand, IL-1β has 
decreased only in rats treated with Me. As for GFAP 
expression, all drugs decreased astrocyte immunostaining 
in the mesencephalon, although Amt, Me and Mo caused 
increased GFAP reactivity in the NAc. Thus, it can be 
assumed that the pain relievers Gb, Me and Mo (even with 
the therapeutic doses that were employed in this study) 
impaired IL-1β and/or TNF-α release. On the other hand, 
all drugs seemed to modify astrocytic expression of GFAP, 
but the effect varied according to the region observed 
(Amt, Gb, Me and Mo decreased this expression in the 
mesencephalon, while Amt, Me and Mo increased it in the 
NAc, probably due to the augmented activity of astrocytes 
in removing the excess of dopamine). 
It is important to notice that the pain relievers used in 
this investigation affected astrocyte behavior and cytokine 
release in healthy rats that were not submitted to painful 
conditions, even though it was not possible to determine 
which cells had the cytokine production impaired. 
Astrocytes appeared to phenotypically react to distinct 
classes of pain modulators, probably influencing neurons 
and the entire CNS microenvironment in physiological 
conditions. Further studies must be performed in order to 
make clear the effects of these pain relievers on astrocytes 
from other CNS regions, both in the absence and in the 
presence of noxious stimuli.
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